Novavax (NVAX) Misses Q4 EPS by 1c, Beats on Revenues
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $9.40 --0%
EPS Growth %: -164.5%
Financial Fact:
Net loss: -66.25M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: -164.5%
Financial Fact:
Net loss: -66.25M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Note: EPS may not be comparable
Novavax (NASDAQ: NVAX) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $7.98 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
- Fiserv (FISV) PT Lowered to $62 at Baird, 'designating as a bearish Fresh Pick into earnings'
- ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
